Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.42 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CPN1 | P15169 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21561140 | 0.89 | OPRM1 (0.44) | EPHX2ALDH1A1 | |
| SCHEMBL24972572 | 0.88 | CHRNB2 (0.44) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL19229731 | 0.88 | CHRNB2 (0.44) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL2603234 | 0.86 | ALDH1A1 (0.41) | EPHX2ALDH1A1NPC1CPN1CPB2 | |
| SCHEMBL13245899 | 0.86 | EPHX2 (0.49) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL12125442 | 0.84 | CPN1 (0.58) | EPHX2ALDH1A1NPC1CPN1CPB2 | |
| SCHEMBL24549763 | 0.84 | ALDH1A1 (0.63) | EPHX2ALDH1A1NPC1CPN1CPB2 | |
| SCHEMBL7919921 | 0.84 | NPC1 (0.48) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL12384441 | 0.84 | POLB (0.56) | EPHX2ALDH1A1NPC1 | |
| SCHEMBL14018532 | 0.84 | EPHX2 (0.47) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023096995-A1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED N-(2-CHLORO-6-METHYLPHENYL)-2-((6-(6-MEMBERED HETEROCYCLOALKYL)-2-METHYLPYRIMIDIN-4-YL)AMINO)THIAZOLE-5-CARBOXAMIDE ANALOGUES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
| US-9040516-B2 | Uracil derivative and use thereof for medical purposes | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-8962642-B2 | 5-cyano-4- (pyrrolo [2,3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140045812-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| US-8530489-B2 | 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110046131-A1 | PURINES AS PKC-THETA INHIBITORS | N.V. Organon and Pharmacopeia, LLC | 2011-02-24 | — | — | US | disclosed |
| US-7786159-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | EPHX2 1339/4885ALDH1A1 983/4885CHRNB2 2107/4885 |
| US-20140045812-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K5, CDK5, MAP4K2 | EPHX2 1685/4885ALDH1A1 3982/4885CHRNB2 3948/4885 |
| US-20110046131-A1 | PURINES AS PKC-THETA INHIBITORS | PRKCQ, PRKCE, PRKCH | EPHX2 1417/4885ALDH1A1 4413/4885CHRNB2 143/4885 |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | EPHX2 994/4885ALDH1A1 576/4885CHRNB2 1155/4885 |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | EPHX2 1281/4885ALDH1A1 945/4885CHRNB2 297/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | EPHX2 4282/4885ALDH1A1 3363/4885CHRNB2 2549/4885 |
| US-20080139621-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | EPHX2 2108/4885ALDH1A1 2613/4885CHRNB2 4517/4885 |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | EPHX2 289/4885ALDH1A1 748/4885CHRNB2 4585/4885 |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | EPHX2 994/4885ALDH1A1 576/4885CHRNB2 1155/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | EPHX2 173/4885ALDH1A1 1138/4885CHRNB2 4577/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885ALDH1A1 2776/4885CHRNB2 4503/4885 |
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | URB2, ELANE, NUDT1 | EPHX2 938/4885ALDH1A1 171/4885CHRNB2 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.